{
    "organizations": [],
    "uuid": "e83c5ab844ce3144a63d3b2c0bbd1fa78288f04c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-grants-breakthrough-therapy-de/brief-fda-grants-breakthrough-therapy-designation-to-omeros-masp-2-inhibitor-oms721-idUSASO0003WZ",
    "ord_in_thread": 0,
    "title": "FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - Omeros Corp:\n* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO OMEROSâ€™ MASP-2 INHIBITOR OMS721 FOR THE TREATMENT OF HIGH-RISK HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY\n* DISCUSSIONS ONGOING WITH FDA AND EUROPEAN REGULATORS FOR EXPEDITED APPROVAL OF OMS721 Source text for Eikon:\n ",
    "published": "2018-04-27T03:02:00.000+03:00",
    "crawled": "2018-04-27T17:15:18.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "omeros",
        "corp",
        "fda",
        "grant",
        "breakthrough",
        "therapy",
        "designation",
        "omeros",
        "inhibitor",
        "oms721",
        "treatment",
        "hematopoietic",
        "stem",
        "cell",
        "thrombotic",
        "microangiopathy",
        "discussion",
        "ongoing",
        "fda",
        "european",
        "regulator",
        "expedited",
        "approval",
        "oms721",
        "source",
        "text",
        "eikon"
    ]
}